- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Srdan Verstovsek, MD, PhD | Authors
Articles
Remaining Unmet Needs and Future Directions in MF
April 19, 2022
Video
Srdan Verstovsek, MD, PhD, wraps up by discussing remaining unmet needs and hopes for future treatment options for patients with MF.
Considerations for Patient Follow-Up and Management
April 19, 2022
Video
A commentary on considerations for long-term follow-up and management of myelofibrosis.
Risk of AML and Potential Use of Bone Marrow Transplant in Patients with MF
April 19, 2022
Video
Srdan Verstovsek, MD, PhD, discusses the risk of transformation to acute myeloid leukemia (AML) and the potential use of bone marrow transplant in patients with MF.
Benefits of Clinical Trial Enrollment for Patients with MF
April 19, 2022
Video
A discussion of the benefits of clinical trial enrollment for MF.
JAK Inhibitors: Impact on Symptoms, Quality of Life, and Patient Outcomes in MF
April 19, 2022
Video
Srdan Verstovsek, MD, PhD, reviews how treatment with JAK inhibitors improves symptoms, quality of life, and patient outcomes in primary MF.
Safety Data on Ruxolitinib in Primary MF
April 19, 2022
Video
Srdan Verstovsek, MD, PhD, comments on safety data from the ruxolitinib clinical trials in patients with MF.